Finding the right affinity ligand pair is a bottleneck in immunoassay development where the Optimer platform can help. Whether you need an additional reagent to form an aptamer-antibody pair or…

Drugs of abuse tests require highly selective, robust assays. Aptamers are helping to deliver new assays for more sensitive and simpler tests. According to the UN Office on Drugs…

Anti-hapten antibodies are difficult and slow to generate limiting cheap and efficient bioanalysis in this field. Our proprietary methods offer standard assay formats, such as ELISA and lateral flow…

Detecting and quantifying small molecule analytes can be difficult. Our specially designed displacement approach allows us to select aptamers that can directly be used in various biosensor platforms for…

The world is facing a global pandemic associated with the COVID-19 virus, for which virulence and infectious dose data are still emerging. With almost 3,025,732 confirmed cases of COVID-19…

5th February 2019 Aptamer Group recently collaborated with a commercial partner to develop aptamers to a variety of small molecule drugs and their active metabolites for biosensor based…